Introduction: The Challenge of Cartilage Repair

Cartilage is a highly specialized connective tissue that provides smooth, low-friction surfaces for joints and acts as a shock absorber. Unlike many other tissues in the body, cartilage has a very limited intrinsic healing capacity due to its avascular nature, low cellular density, and the lack of a direct blood supply. Damage to articular cartilage — whether from acute injury, repetitive loading, or degenerative diseases such as osteoarthritis — often leads to progressive joint deterioration, chronic pain, and functional disability. Traditional treatment strategies, including microfracture, autologous chondrocyte implantation, and osteochondral grafting, aim to alleviate symptoms and restore some function but rarely regenerate the native hyaline cartilage architecture. In recent years, gene therapy has emerged as a transformative approach, offering the potential to deliver therapeutic proteins directly to damaged cartilage to stimulate true regeneration rather than mere symptom management.

Gene therapy for cartilage regeneration involves the transfer of genetic material into target cells — either in vivo (directly into the joint) or ex vivo (cells harvested, genetically modified, and reimplanted) — to produce specific growth factors, transcription factors, or anti‑inflammatory molecules. This strategy can promote chondrogenesis, enhance extracellular matrix production, modulate the inflammatory environment, and even reverse catabolic processes. While still in the early stages of clinical translation, preclinical studies have demonstrated impressive results, and ongoing clinical trials are beginning to assess safety and efficacy in human patients.

Fundamental Principles of Gene Therapy for Cartilage

The core concept of gene therapy is to introduce exogenous nucleic acids into cells to achieve a therapeutic effect. In the context of cartilage repair, this typically means delivering genes that encode for anabolic growth factors (e.g., TGF‑β, BMP‑2, BMP‑7, IGF‑1), transcription factors that drive chondrogenesis (e.g., SOX9), or inhibitors of catabolic enzymes (e.g., IL‑1 receptor antagonists). The success of these approaches depends on several key factors: the choice of vector, the route of administration, the duration of gene expression, and the control of potential immune responses.

In Vivo Versus Ex Vivo Strategies

In vivo gene therapy involves direct injection of the gene‑carrying vector into the joint space (intra‑articular delivery) or into the cartilage lesion itself. This approach is less invasive and can be performed as a single procedure. However, it requires efficient transduction of chondrocytes or synovial cells in situ and carries risks of vector dissemination and off‑target effects.

Ex vivo gene therapy involves harvesting autologous cells — such as articular chondrocytes, mesenchymal stem cells (MSCs), or synovial‑derived stem cells — transducing them with the therapeutic gene in the laboratory, and then reimplanting them into the cartilage defect, often seeded on a scaffold. This strategy allows for careful control of the modification process, selection of transduced cells, and removal of non‑target cells. Ex vivo approaches are generally considered safer but are more complex, costly, and require two surgical procedures.

Gene Delivery Methods: Vector Technologies

Efficient and safe delivery of therapeutic genes is the cornerstone of any gene therapy regimen. The vectors used for cartilage regeneration fall into two broad categories: viral and non‑viral. Each has distinct advantages and limitations that influence their suitability for clinical application.

Viral Vectors

Viral vectors are derived from viruses that have been modified to remove pathogenic genes while retaining their ability to enter cells and deliver genetic payloads. They are highly efficient at transducing both dividing and non‑dividing cells, which is particularly important for chondrocytes, which have a low proliferation rate in situ.

  • Adeno‑Associated Virus (AAV): AAV vectors are among the most widely used in clinical gene therapy for cartilage. They are non‑pathogenic, elicit mild immune responses, and can provide long‑term gene expression in non‑dividing cells. Multiple serotypes (e.g., AAV2, AAV5, AAV8) have been studied for their tropism to chondrocytes and synovium. AAV vectors have been used to deliver TGF‑β, BMP‑7, and IL‑1Ra in preclinical models, leading to improved cartilage repair and reduced inflammation.
  • Lentiviral Vectors: Derived from HIV‑1, lentiviral vectors can transduce both dividing and non‑dividing cells and integrate the transgene into the host genome, enabling stable long‑term expression. This is advantageous for chronic conditions like osteoarthritis. However, integration carries a risk of insertional mutagenesis, which must be carefully managed. Lentiviral vectors have been explored for ex vivo transduction of MSCs and chondrocytes, showing sustained production of therapeutic proteins.
  • Adenoviral Vectors: Adenoviral vectors can achieve high levels of transgene expression, but they do not integrate and are prone to triggering strong immune responses, leading to transient expression. They are less favored for cartilage gene therapy due to the risk of inflammation, which could exacerbate joint damage.
  • Retroviral Vectors (γ‑retrovirus): Similar to lentiviral vectors but only transduce dividing cells. They have been used in some ex vivo studies but are increasingly supplanted by lentiviral and AAV systems.

Non‑Viral Vectors

Non‑viral delivery methods offer several advantages: lower immunogenicity, easier manufacturing, larger carrying capacity, and reduced risk of insertional mutagenesis. However, they generally achieve lower transfection efficiency and shorter expression duration compared to viral vectors.

  • Plasmid DNA (naked DNA): Simple and safe, but transfection efficiency in chondrocytes is poor without additional delivery aids. Electroporation or sonoporation can enhance uptake but may cause tissue damage.
  • Liposomes and Cationic Polymers: Lipid‑based nanoparticles (lipoplexes) and polymers such as polyethylenimine (PEI) can condense DNA and facilitate cellular entry via endocytosis. Modifications with targeting ligands (e.g., collagen‑binding peptides) can improve chondrocyte specificity. Non‑viral vectors are often used in gene‑activated matrices.
  • Gene‑Activated Matrices (GAMs): These combine scaffold materials (collagen, hyaluronic acid, fibrin, or synthetic polymers) with plasmid DNA encoding therapeutic genes. When implanted into a cartilage defect, the scaffold provides structural support while resident cells take up the DNA and express the protein. GAMs are particularly appealing because they simplify the delivery process and can be tailored to release the gene over time.
  • mRNA‑Based Approaches: More recently, modified mRNA (ranging from synthetic to chemically modified) has been investigated as an alternative to DNA‑based gene therapy. mRNA does not need to enter the nucleus, poses no risk of genomic integration, and provides transient but potent protein expression. This is advantageous for acute cartilage injuries where short‑term anabolic stimulation is desired.

Target Genes for Cartilage Regeneration

Selecting the appropriate therapeutic gene is crucial. The ideal gene should promote chondrogenesis, stimulate production of cartilage‑specific extracellular matrix (collagen type II and aggrecan), inhibit catabolic enzymes, and reduce inflammation. Several key genes have emerged as promising candidates.

SOX9: The Master Regulator of Chondrogenesis

SOX9 is a transcription factor essential for chondrocyte differentiation and cartilage formation. It directly upregulates the expression of collagen type II, aggrecan, and other matrix proteins. Overexpression of SOX9 in MSCs or chondrocytes has been shown to enhance chondrogenesis in vitro and improve cartilage repair in vivo. Studies using AAV‑SOX9 in rat and rabbit models have demonstrated better histological scores and increased type II collagen deposition compared to controls. One challenge is that sustained high SOX9 expression can lead to hypertrophic chondrocyte phenotypes, so precise regulation of expression levels is important.

Transforming Growth Factor Beta (TGF‑β)

TGF‑β (particularly isoform β1) is a potent anabolic factor that stimulates chondrocyte proliferation and matrix synthesis while inhibiting matrix metalloproteinases (MMPs) and aggrecanases. TGF‑β has been delivered via both viral and non‑viral vectors in numerous preclinical studies. For example, injection of AAV‑TGF‑β1 into osteoarthritic mouse knees reduced cartilage degradation and prevented osteophyte formation. However, TGF‑β can also induce fibrosis and osteophyte formation if not tightly controlled. Its pro‑fibrotic effects require careful dose and duration management, often necessitating the use of inducible or tissue‑specific promoters.

Bone Morphogenetic Proteins (BMPs)

BMPs, particularly BMP‑2, BMP‑4, BMP‑6, and BMP‑7 (also known as OP‑1), are members of the TGF‑β superfamily that are well‑known for their roles in bone and cartilage development. BMP‑7 has been extensively studied as a therapeutic for cartilage repair. It promotes chondrocyte anabolism, stimulates proteoglycan synthesis, and can reverse some catabolic effects of interleukin‑1. Clinical trials using recombinant BMP‑7 protein (not gene therapy) showed some promise but required repeated injections. Gene therapy delivery of BMP‑7 via AAV or adenoviral vectors has demonstrated sustained cartilage protection in animal models of osteoarthritis. BMP‑2 expression in MSCs can drive chondrogenesis but may also trigger endochondral ossification if signaling is prolonged or at high levels.

Insulin‑Like Growth Factor 1 (IGF‑1)

IGF‑1 is another anabolic factor that promotes proteoglycan and collagen synthesis while inhibiting matrix degradation. It has been delivered using both viral and non‑viral vectors. In a notable study, lentiviral delivery of IGF‑1 to MSCs implanted in a minipig cartilage defect led to improved tissue quality and integration. IGF‑1 is generally considered safer than TGF‑β in terms of fibrosis risk, but its therapeutic window is narrower, and its effects may be less potent in advanced degeneration.

Anti‑Inflammatory and Anti‑Catabolic Genes

In addition to anabolic factors, genes that block catabolic and inflammatory pathways are being explored. For instance, the IL‑1 receptor antagonist (IL‑1Ra) gene can neutralise the effects of IL‑1β, a key driver of cartilage degradation in osteoarthritis. Intra‑articular delivery of IL‑1Ra using AAV or non‑viral vectors has been shown to reduce cartilage loss and pain in animal models. Similarly, overexpression of tissue inhibitors of metalloproteinases (TIMPs) can inhibit MMP activity and preserve matrix integrity.

Preclinical Research and Animal Models

A wealth of preclinical studies has established the proof‑of‑concept for gene therapy in cartilage regeneration. Early work in rabbits, rats, and sheep using ex vivo transduction of chondrocytes with TGF‑β or BMP‑7 showed improved defect filling with hyaline‑like tissue. More recent studies have employed small animal models (mice, rats) for mechanistic studies and large animals (goats, sheep, minipigs) for translational research.

For example, a 2023 study published in Nature Reviews Endocrinology reviewed various gene therapy strategies and highlighted that AAV‑mediated delivery of an IL‑1Ra/TGF‑β1 fusion gene resulted in synergistic benefits in a rat model of osteoarthritis. Another study using a minipig model demonstrated that implantation of MSCs transduced with a lentiviral vector encoding SOX9 and TGF‑β3 led to robust cartilage regeneration at 24 weeks, with biomechanical properties approaching those of native tissue.

These studies consistently show that gene therapy can achieve superior structural and functional repair compared to cell‑only or scaffold‑only treatments. However, the duration of transgene expression, vector‑related inflammation, and potential for off‑target effects remain significant concerns.

Clinical Trials and Human Applications

As of early 2025, several clinical trials have been initiated to evaluate gene therapy for cartilage repair, though most are in early phases (I‑II) focusing on safety and tolerability. One of the earliest trials used a retroviral vector to transduce autologous chondrocytes with the TGF‑β1 gene (ex vivo retroviral therapy). Published results from a small cohort showed improvements in clinical outcome scores (WOMAC, VAS pain) and MRI‑based tissue filling over two years, with no serious adverse events.

Another approach uses a non‑viral, plasmid‑based system delivered via a scaffold. A company called TissueGene has developed a therapy (TG‑C) that uses allogeneic chondrocytes transduced with a retroviral vector expressing TGF‑β1 (invossa). After initial promise, the trial faced regulatory setbacks but is being redesigned. More recently, an AAV‑based therapy encoding a soluble TNF receptor (sTNFR) has been tested in patients with osteoarthritis, aiming to block TNF‑α activity within the joint.

The first FDA‑approved gene therapy for a musculoskeletal condition — though not specifically cartilage — was for spinal muscular atrophy. The success of AAV‑based systemic gene therapies has renewed interest in applying similar technologies to joint diseases. A clinical trial listed on ClinicalTrials.gov (identifier NCT05038462) is investigating a single intra‑articular injection of an AAV vector expressing IL‑1Ra in patients with knee osteoarthritis. Preliminary results have shown acceptable safety and trends toward pain reduction.

While these early‑stage trials provide optimism, it will take several more years before any gene therapy for cartilage regeneration gains regulatory approval for widespread clinical use. The complexities of dose optimization, vector immunogenicity, and long‑term safety monitoring are being addressed step by step.

Challenges and Limitations

Despite the promise, significant hurdles remain.

Immune Responses

The host immune system can recognize viral vectors (especially AAV and adenovirus) and trigger inflammatory reactions that may eliminate transduced cells and cause joint inflammation. Pre‑existing or induced neutralizing antibodies against AAV serotypes can limit transduction efficiency. Strategies to mitigate this include using immunosuppression at the time of delivery, switching serotypes, or modifying vector capsids to evade immune detection. Non‑viral vectors generally avoid this issue but suffer from low efficiency.

Duration of Gene Expression

For chronic diseases like osteoarthritis, sustained expression may be desired over months or years. Integrating vectors (lentivirus) provide permanent expression but carry oncogenic risks. Non‑integrating vectors (AAV, adenovirus) can persist as episomes, but expression may wane with cell division or immune clearance. For acute cartilage defects, transient expression may be sufficient, making non‑viral or mRNA approaches attractive.

Delivery Efficiency

Efficient transduction of chondrocytes within dense cartilage matrix is challenging. The dense extracellular matrix acts as a barrier to vectors. Direct intra‑articular injection may transduce synovial lining cells more efficiently than chondrocytes. Many studies rely on ex vivo transduction of cells that are then implanted, which avoids this barrier but complicates clinical workflow. Gene‑activated matrices offer a compromise.

Oncogenicity and Off‑Target Effects

Integrating vectors carry a risk of insertional mutagenesis, potentially causing cancer. Although no such events have been reported in cartilage gene therapy studies to date, the risk must be minimized. Additionally, overexpression of growth factors like TGF‑β and BMPs may lead to osteophyte formation, fibrosis, or even tumorigenesis if systemic dissemination occurs. Controlled expression using inducible or tissue‑specific promoters is an active area of research.

Emerging Strategies and Future Directions

Several innovations are poised to overcome current limitations.

CRISPR‑Based Gene Editing

Rather than delivering a therapeutic transgene, CRISPR‑Cas systems can be used to edit endogenous genes in chondrocytes or stem cells. For example, activating the SOX9 locus by targeting a dCas9‑VP64 fusion protein could upregulate chondrogenesis without introducing exogenous DNA. Alternatively, editing genes involved in catabolic pathways (e.g., IL‑1β or MMP13) could protect cartilage from degradation. Early in vitro evidence is promising, but delivery of CRISPR components to joint tissues remains a challenge.

Smart Vectors and Targeted Delivery

Researchers are developing vectors with improved tropism for chondrocytes. This includes engineering AAV capsids to display peptides that bind cartilage matrix components (e.g., collagen type II binding peptides) or targeting mesenchymal stem cells recruited to the injury site. Theranostic vectors that combine gene delivery with imaging capabilities are also being explored.

Combination Therapies

Gene therapy may be most effective when combined with cell therapy, scaffolds, and controlled release mechanisms. For instance, delivering both an anabolic gene (TGF‑β) and an anti‑catabolic gene (IL‑1Ra) in a single vector or co‑delivering multiple genes. Such combination treatments better mimic the complex biological environment needed for true regeneration.

Personalised Medicine

Patient‑specific factors, including genetic background, disease stage, and immune status, will likely influence the success of gene therapy. Future protocols may involve patient‑derived induced pluripotent stem cells (iPSCs) genetically corrected and differentiated into chondrocytes for implantation. The cost and complexity of such approaches remain prohibitive for now, but advances in manufacturing may make them feasible.

Conclusion

Gene therapy for cartilage regeneration represents a paradigm shift from palliation to restoration. By directly targeting the molecular drivers of cartilage degradation and supplying anabolic factors in a sustained manner, these approaches have the potential to achieve what conventional treatments cannot: the formation of durable, hyaline‑like cartilage. Preclinical evidence is strong, and early clinical trials are laying the groundwork for eventual regulatory approval. Yet, challenges related to vector safety, immune responses, delivery efficiency, and precise control of gene expression must be resolved. As vector technology improves, gene editing becomes more accurate, and combination therapies are refined, gene therapy is expected to become a cornerstone of regenerative orthopaedics. The journey from bench to bedside is ongoing, but the trajectory promises a future where joint cartilage can be truly regenerated, improving the quality of life for millions affected by cartilage damage and osteoarthritis.